Social Anxiety
Neurology
0
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Jerusalem PharmaceuticalsIsrael - Ramallah
3 programsImaginal RescriptingN/A1 trial
Imaginal exposure for memoriesN/A1 trial
Imaginal exposure one-sessionN/A1 trial
Active Trials
J&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Johnson & JohnsonDSB-I
Jerusalem PharmaceuticalsImaginal exposure for memories
Jerusalem PharmaceuticalsImaginal exposure one-session
Jerusalem PharmaceuticalsImaginal Rescripting
Clinical Trials (4)
Total enrollment: 616 patients across 4 trials
Intervention to Reduce Safety Behaviors
Start: Jul 2024Est. completion: Dec 202523 patients
N/ACompleted
Imagery Rescripting and Imaginal Exposure for Anxiety Symptoms
Start: Apr 2022Est. completion: Jan 2025460 patients
N/AUnknown
Imagery Rescripting and Imaginal Exposure for Social Anxiety: Mechanisms and Outcomes in an Analog Sample
Start: Apr 2021Est. completion: Aug 2023100 patients
N/AUnknown
Treating Negative Mental Images and Memories in Social Anxiety
Start: May 2017Est. completion: Aug 201833 patients
N/ACompleted
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
7h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
7h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
7h ago
Director of Finance
CoMind
London, UK
7h ago
Electronics Engineering Manager
CoMind
London, UK
7h ago
Director of Information Technology
Zavation Medical Products
7h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space